施维雅完成对Day One Biopharmaceuticals的收购-动脉网

Servier completes the acquisition of Day One Biopharmaceuticals

CISION 等信源发布 2026-04-23 20:30



可切换为仅中文







Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDA

收购扩大了施维雅在肿瘤学领域的地位，tovorafenib以OJEMDA品牌上市。

商标符号 (™)

in the U.S

在美国

。

in pediatric low-grade glioma.

在小儿低级别胶质瘤中。

Transaction also includes a

交易还包括

strong oncology pipeline of clinical stage assets

强大的临床阶段肿瘤学资产管道

in rare cancers with high unmet needs.

在罕见且未满足需求高的癌症中。

Transaction represents total equity value of approximately $2.5 billion.

交易代表了约25亿美元的总股权价值。

SURESNES, France

法国叙雷讷

，

April 23, 2026

2026年4月23日

/PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced the successful completion of the tender offer to acquire all of the issued and outstanding shares of common stock of Day One Biopharmaceuticals, Inc. (Nasdaq:

/PRNewswire/ -- Servier，一家由基金会管理的独立国际制药集团，今天宣布成功完成了对Day One Biopharmaceuticals, Inc.（纳斯达克：）所有已发行和流通在外的普通股的要约收购。

DAWN

黎明

) ('Day One'), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, for $21.50 per share. The acquisition strengthens Servier's leadership in low-grade glioma and expands the Group's position in oncology with the addition of a marketed product and pipeline focused on rare cancers..

）（“第一天”），一家致力于为所有年龄段的患有危及生命疾病的患者开发和商业化靶向疗法的生物制药公司，收购价为每股21.50美元。此次收购加强了施维雅在低级别胶质瘤领域的领导地位，并通过增加已上市产品和专注于罕见癌症的管线，扩展了集团在肿瘤学领域的地位。

继续阅读

View PDF

查看PDF

Servier completes the acquisition of Day One Biopharmaceuticals

施维雅完成对Day One生物制药公司的收购

'This acquisition represents a significant step forward for Servier as part of our 2030 ambition to strengthen our position in rare cancers, and more specifically in pediatric low-grade glioma,' said

“此次收购标志着赛维雅在实现2030年愿景的道路上迈出了重要一步，我们的目标是加强在罕见癌症领域的地位，特别是儿童低级别胶质瘤领域，”

Olivier Laureau, President of Servier

施维雅公司总裁奥利维尔·拉罗雷

. 'Integrating Day One's scientific and clinical capabilities will enhance our Group's ability to support long-term innovation and translate science into meaningful medicines for children and families affected by rare cancers.'

“整合Day One的科学和临床能力将增强我们集团支持长期创新并将科学转化为对受罕见癌症影响的儿童和家庭有意义的药物的能力。”

Day One's portfolio includes OJEMDA

第一天的资产组合包括OJEMDA。

商标

(tovorafenib), an FDA-approved medicine in pediatric low-grade glioma, the most common form of childhood brain tumor. Day One already markets the product in the United States and has licensed the rights outside the U.S. to Ipsen.

（托沃拉非尼），一种FDA批准的用于儿童低级别胶质瘤的药物，这是最常见的儿童脑肿瘤类型。Day One公司已在美国市场推出该产品，并将美国以外的权利授权给了Ipsen公司。

The transaction also strengthens Servier's oncology pipeline from early clinical to Phase 3. In addition to tovorafenib, which is being investigated in additional indications, Day One's pipeline includes Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate (ADC) and DAY301, a targeted therapy in rare cancers. .

该交易还加强了施维雅从早期临床到第三阶段的肿瘤学管线。除了正在其他适应症中进行研究的托沃拉非尼外，Day One的管线还包括Emi-Le（艾米塔图格-莱达多汀），一种新型抗体药物偶联物（ADC），以及DAY301，一种针对罕见癌症的靶向疗法。

'Welcoming Day One to Servier marks an important next chapter in how we are expanding our presence in oncology in the U.S. and strengthening our ability to deliver for patients,'

“欢迎第一天加入施维雅标志着我们在美国扩展肿瘤学领域的重要新篇章，并加强了我们为患者提供服务的能力，”

said David K. Lee, Executive Vice President, USA, and CEO, Servier Pharmaceuticals

美国执行副总裁、施维雅制药首席执行官David K. Lee说

. 'Day One is joining us with strong science, an approved medicine, and a team that knows how to turn innovation into real outcomes for patients. This is about combining focus with execution to deliver for patients with rare cancers.'

“Day One带着强大的科学、获批的药物以及懂得如何将创新转化为患者实际成果的团队加入我们。这是关于结合专注与执行力，为罕见癌症患者提供服务。”

Contacts

联系人

Servier Group

赛诺菲集团

Laura Visserias

劳拉·维瑟里亚斯

[email protected]

电子邮件地址

Servier Pharmaceuticals (U.S.)

施维雅制药（美国）

Paulina Bucko